Close Menu

NEW YORK – Pfizer on Wednesday announced that its third-generation TKI lorlatinib (Lorbrena) achieved its primary endpoint of improved progression-free survival in the Phase III CROWN trial, and accordingly, the New York-based drug giant intends to seek US Food and Drug Administration (FDA) approval for the agent in previously untreated ALK-positive metastatic NSCLC.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.